1 / 6

Afatinib: As a Monotherapy for NSCLC

Afatinib is approved as a monotherapy for the treatment of adult patients with locally advanced/metastatic NSCLC with activating epidermal growth factor receptor (EGFR) mutations. The afatinib for non-small cell lung cancer comes only as a tablet for oral (by mouth) administration. Take afatinib tablets exactly as directed. Do not take more or fewer doses or take it quite often than prescribed by your health specialist. This medication targets certain proteins named EGF receptors within non-small cell lung cancer cells. This action inhibits cancer from growing and spreading. In most nations

23914
Download Presentation

Afatinib: As a Monotherapy for NSCLC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MEDICATION TO TREAT NON-SMALL CELL LUNG CARCINOMA

  2. What is Afatinib? • An irreversible TKI (tyrosine kinase inhibitor) that blocks the EGFR (epidermal growth factor receptor) ErbB1 and other respective members of the family of ErbB.  • Afatinib known as the monotherapy for treating EGFR tyrosine kinase inhibitor-naive adult patients who have the locally advanced or metastatic NSCLC (non-small-cell lung cancer) with the activating EGFR mutation.

  3. AfatinibSide Effects: Most common reactions for afatinib: • Diarrhoea • Rash • Dry skin conditions • Decreased appetite • Paronychia

  4. Afatinib Dosage Afatinibtablets should be given orally at a recommended dosage of 40 mg once daily. The dosage can be enhanced to the maximum of 50 mg per day in the initial 21 days in such patients who are capable in order to tolerate the afatinib 40 mg per day without adverse events of more than the grade one severity. 

  5. How to store Afatinib: • Do not use, if it is out of date which is mentioned on the carton.  • Should be stored in the original package to protect from light as well as moisture. • Never throw afatinib via wastewater or through the household waste.

  6. NOTE: The piece of information provided about "AFATINIB: A SPECIFIC MEDICATION TO TREAT NON-SMALL CELL LUNG CARCINOMA" in this article is just for informational purposes and is not served as a substitute for the medical treatment, consultation, diagnosis of an experienced or qualified healthcare practitioner. Source: http://the-indian-pharma.over-blog.com/afatinib-a-specific-medication-to-treat-non-small-cell-lung-carcinoma.html

More Related